Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Carl Gommoll"'
Autor:
Cheng-Tao Chang, Suresh Durgam, Michael E. Thase, Michelle Aguirre, Carl Gommoll, Changzheng Chen, Raffaele Migliore
Publikováno v:
International Clinical Psychopharmacology
Supplemental Digital Content is available in the text.
This randomized withdrawal study assessed relapse prevention with vilazodone in adults with major depressive disorder. After 20 weeks of open-label treatment with vilazodone 40 mg/day, respo
This randomized withdrawal study assessed relapse prevention with vilazodone in adults with major depressive disorder. After 20 weeks of open-label treatment with vilazodone 40 mg/day, respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef0a8a6aa9f9aeeb87defb4eb2706397
https://doi.org/10.1097/yic.0000000000000236
https://doi.org/10.1097/yic.0000000000000236
Autor:
Changzheng Chen, Michael E. Thase, Maju Mathews, John Edwards, Carl Gommoll, Suresh Durgam, Cheng-Tao Chang
Publikováno v:
International Clinical Psychopharmacology
Treatment-emergent suicidal ideation and behavior are ongoing concerns with antidepressants. Vilazodone, currently approved for the treatment of major depressive disorder (MDD) in adults, has also been evaluated in generalized anxiety disorder (GAD).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31893823636d924e3f08b9351594bb57
https://doi.org/10.1097/yic.0000000000000180
https://doi.org/10.1097/yic.0000000000000180
Publikováno v:
Journal of Affective Disorders. 210:273-279
To evaluate the effects of levomilnacipran extended-release (LVM-ER; 40-120mg/day) on noradrenergic (NA) and anxiety-related symptoms in adults with major depressive disorder (MDD) and explore the relationship between these symptoms and functional im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29b6a3e4f94f6df13376f233a96a9248
Publikováno v:
Neuropsychiatric Disease and Treatment
Background In three 8-week studies of vilazodone 40 mg/d (NCT00285376, NCT00683592, and NCT01473394) and a 10-week study of vilazodone 20 or 40 mg/d (NCT01473381), adults with major depressive disorder (MDD) showed significantly greater improvement w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eee50484f9651605a1413c52af3b783b
http://europepmc.org/articles/PMC5144912
http://europepmc.org/articles/PMC5144912
Publikováno v:
International Clinical Psychopharmacology
Supplemental Digital Content is available in the text.
The objective of this post-hoc analysis was to investigate the relationship between motivation/energy and functional impairment in patients with major depressive disorder (MDD). Data were ta
The objective of this post-hoc analysis was to investigate the relationship between motivation/energy and functional impairment in patients with major depressive disorder (MDD). Data were ta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd1a3bf42a625056de6b600d45a64fd6
https://doi.org/10.1097/yic.0000000000000138
https://doi.org/10.1097/yic.0000000000000138
Publikováno v:
CNS Spectrums. 21:385-392
ObjectiveA post hoc analysis evaluated the effects of levomilnacipran ER on individual symptoms and symptom domains in adults with major depressive disorder (MDD).MethodsData were pooled from 5 Phase III trials comprising 2598 patients. Effects on de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9f6c438dd72b571699190cba5c8e285
https://doi.org/10.1017/s1092852915000899
https://doi.org/10.1017/s1092852915000899
Autor:
Suresh Durgam, David V. Sheehan, Giovanna Forero, Xiongwen Tang, Rene Nunez, Carl Gommoll, Maju Mathews
Publikováno v:
The Journal of Clinical Psychiatry. 77:1687-1694
Objective To evaluate the efficacy, safety, and tolerability of vilazodone as an acute treatment for generalized anxiety disorder (GAD). Vilazodone is a selective serotonin reuptake inhibitor and 5-HT1A receptor partial agonist approved for the treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01080a10db9f96c741506d0a8fdb801a
https://doi.org/10.4088/jcp.15m09885
https://doi.org/10.4088/jcp.15m09885
Autor:
Marlene P. Freeman, Changzheng Chen, Carl Gommoll, William M. Greenberg, Adam Ruth, Maurizio Fava
Publikováno v:
International Clinical Psychopharmacology
The aim of this study was to evaluate the effects of levomilnacipran extended-release (ER) on depression-related fatigue in adults with major depressive disorder. Post-hoc analyses of five phase III trials were carried out, with evaluation of fatigue
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96d3367c980e172c8dfb7221d4941b2d
https://doi.org/10.1097/yic.0000000000000104
https://doi.org/10.1097/yic.0000000000000104
Publikováno v:
Journal of Affective Disorders. 193:137-143
BackgroundMajor depressive disorder (MDD) can be challenging to manage due its variable and episodic nature. Post hoc analyses were conducted on five studies (NCT00969709, NCT01377194, NCT00969150, NCT01034462, EudraCT:2006-002404-34) to evaluate the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b54c54e29186ff2263945a259bbe208
https://doi.org/10.1016/j.jad.2015.12.058
https://doi.org/10.1016/j.jad.2015.12.058
Publikováno v:
International clinical psychopharmacology. 33(4)
The efficacy of antidepressants to treat major depressive disorder (MDD) varies by patient characteristics. This post-hoc analysis evaluated the effects of vilazodone across patient subgroups in adults with MDD. Data were pooled from four trials of v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52048944d6578425ff738266cc08944e
https://pubmed.ncbi.nlm.nih.gov/29608461
https://pubmed.ncbi.nlm.nih.gov/29608461